Poniard Pharmaceuticals Files Investigational New Drug Application For Oral Formulation Of Picoplatin

... Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for an oral formulation of picoplatin. Following FDA review, the Company intends to initiate a Phase 1 clinical trial of oral picoplatin. [click link for full article] ...